Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 2.1% – What’s Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 2.1% during trading on Friday . The stock traded as high as $6.54 and last traded at $6.37. 5,629,128 shares changed hands during trading, a decline of 78% from the average session volume of 25,496,789 shares. The stock had previously closed at $6.24.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on RXRX shares. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Price Performance

The business has a fifty day moving average of $7.65 and a 200-day moving average of $7.08. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.57 billion, a PE ratio of -4.30 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the previous year, the company posted ($0.42) EPS. The company’s revenue for the quarter was down 57.8% compared to the same quarter last year. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth $26,000. Private Trust Co. NA purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $27,000. GAMMA Investing LLC boosted its position in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.